Continuity Biosciences Launches Innovative Clinical Trial for Targeted Treatment of Pancreatic Cancer
Continuity Biosciences, a clinical-stage biotechnology firm, has recently announced the commencement of a first-in-human clinical trial designed to evaluate its innovative iontophoretic oncology platform (IOP) for delivering gemcitabine—a commonly used chemotherapy drug—specifically to pancreatic cancer tumors. This is an exciting development in the fight against pancreatic cancer, a disease noted for its high mortality rate and low survival rates despite various treatment options available today.
The clinical trial, officially listed on ClinicalTrials.gov under the identifier NCT07481383, is now open for participant enrollment. It is being conducted at prestigious academic medical centers such as the J.W. Ruby Memorial Hospital associated with WVU Medicine in Morgantown, West Virginia, and the Taubman Center at the University of Michigan in Ann Arbor.
Continuity Biosciences' unique platform seeks to tackle significant obstacles faced by conventional cancer therapies, such as inadequate drug penetration and systemic toxicity. By employing an innovative localized delivery mechanism, the IOP aims to ensure that higher concentrations of the chemotherapy are administered directly to the tumor site while reducing exposure to the rest of the body.
CEO Ramakrishna "Krishna" Venugopalan emphasized the significance of this trial, stating, "This first-in-human study represents an important milestone in our mission to transform how therapies are delivered to solid tumors. By enabling precise, localized delivery, we believe our platform has the potential to enhance the effectiveness of existing therapies and serve as a foundation for combination treatment approaches across multiple tumor types."
Pancreatic cancer is notorious for its aggressive nature and is one of the leading causes of cancer-related deaths globally. Despite recent advances, the survival rates remain alarmingly low, with only a few patients surviving beyond five years after diagnosis. One of the greatest challenges is effectively delivering therapeutic agents to the tumor without adversely affecting healthy tissues, which this trial aims to address.
Dr. Jen Jen Yeh, a noted expert and Director of the Pancreatic Cancer Center of Excellence at UNC Lineberger Comprehensive Cancer Center, expressed urgency for improved treatment strategies, stating, "The current need for better treatment options for pancreatic cancer is critical. It’s a challenge to deliver therapy precisely to the tumor while sparing the rest of the body. This innovative approach could be a game-changer in addressing those challenges."
Furthermore, Dr. Brian Boone, a surgical oncologist and principal investigator for the trial at the WVU Cancer Institute, commented, "This trial is a critical step toward safer and more effective delivery of gemcitabine for pancreatic cancer patients. By targeting therapy directly to the tumor, we hope to improve outcomes while minimizing the side effects often experienced in advanced disease stages."
The IOP is not limited to pancreatic cancer; Continuity Biosciences is actively investigating its application in other cancer types. For example, they are considering how this innovative delivery platform could be utilized for localized therapy in oral head and neck cancers as well.
Continuity Biosciences is dedicated to developing precision drug delivery solutions that can effectively enhance therapy outcomes across diverse disease categories. Their goal is to break down the barriers faced in drug delivery systems, thereby increasing the overall efficiency of cancer treatments and improving patient outcomes worldwide. For more detailed information on their ongoing projects and innovations, one can visit their official website at www.continuitybiosciences.com.
The clinical trial, officially listed on ClinicalTrials.gov under the identifier NCT07481383, is now open for participant enrollment. It is being conducted at prestigious academic medical centers such as the J.W. Ruby Memorial Hospital associated with WVU Medicine in Morgantown, West Virginia, and the Taubman Center at the University of Michigan in Ann Arbor.
Continuity Biosciences' unique platform seeks to tackle significant obstacles faced by conventional cancer therapies, such as inadequate drug penetration and systemic toxicity. By employing an innovative localized delivery mechanism, the IOP aims to ensure that higher concentrations of the chemotherapy are administered directly to the tumor site while reducing exposure to the rest of the body.
CEO Ramakrishna "Krishna" Venugopalan emphasized the significance of this trial, stating, "This first-in-human study represents an important milestone in our mission to transform how therapies are delivered to solid tumors. By enabling precise, localized delivery, we believe our platform has the potential to enhance the effectiveness of existing therapies and serve as a foundation for combination treatment approaches across multiple tumor types."
Pancreatic cancer is notorious for its aggressive nature and is one of the leading causes of cancer-related deaths globally. Despite recent advances, the survival rates remain alarmingly low, with only a few patients surviving beyond five years after diagnosis. One of the greatest challenges is effectively delivering therapeutic agents to the tumor without adversely affecting healthy tissues, which this trial aims to address.
Dr. Jen Jen Yeh, a noted expert and Director of the Pancreatic Cancer Center of Excellence at UNC Lineberger Comprehensive Cancer Center, expressed urgency for improved treatment strategies, stating, "The current need for better treatment options for pancreatic cancer is critical. It’s a challenge to deliver therapy precisely to the tumor while sparing the rest of the body. This innovative approach could be a game-changer in addressing those challenges."
Furthermore, Dr. Brian Boone, a surgical oncologist and principal investigator for the trial at the WVU Cancer Institute, commented, "This trial is a critical step toward safer and more effective delivery of gemcitabine for pancreatic cancer patients. By targeting therapy directly to the tumor, we hope to improve outcomes while minimizing the side effects often experienced in advanced disease stages."
The IOP is not limited to pancreatic cancer; Continuity Biosciences is actively investigating its application in other cancer types. For example, they are considering how this innovative delivery platform could be utilized for localized therapy in oral head and neck cancers as well.
Continuity Biosciences is dedicated to developing precision drug delivery solutions that can effectively enhance therapy outcomes across diverse disease categories. Their goal is to break down the barriers faced in drug delivery systems, thereby increasing the overall efficiency of cancer treatments and improving patient outcomes worldwide. For more detailed information on their ongoing projects and innovations, one can visit their official website at www.continuitybiosciences.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.